|
Guarantor and Non-Guarantor Financial Statements - Condensed Consolidating Statements of Cash Flow (Detail) (USD $)
In Millions, unless otherwise specified
|
9 Months Ended |
|
Feb. 28, 2014
|
Feb. 28, 2013
|
| Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] |
|
|
| Cash flows provided by (used in) operating activities |
$ 325.6 |
$ 273.8 |
| Proceeds from sales/maturities of investments |
19.0 |
5.5 |
| Purchases of investments |
(19.8) |
(6.4) |
| Capital expenditures |
(158.8) |
(149.7) |
| Acquisitions, net of cash acquired - 2013 Spine Acquisition |
(148.8) |
0 |
| Acquisitions, net of cash acquired |
0 |
(280.0) |
| Other |
(1.3) |
(4.1) |
| Net cash used in investing activities |
(308.9) |
(433.8) |
| Payments under senior secured credit facilities |
(22.6) |
(25.2) |
| Proceeds under revolvers |
159.3 |
80.0 |
| Payments under revolvers |
(63.0) |
(80.0) |
| Proceeds from senior notes due 2020 and term loans |
870.5 |
3,396.2 |
| Tender/retirement of senior notes due 2017 and term loans |
(1,091.6) |
(3,423.0) |
| Payment of fees related to refinancing activities |
(15.5) |
(77.8) |
| Other |
(39.8) |
(26.3) |
| Net cash used in financing activities |
(164.6) |
(130.9) |
| Effect of exchange rate changes on cash |
4.7 |
15.9 |
| Increase (decrease) in cash and cash equivalents |
(143.2) |
(275.0) |
| Cash and cash equivalents, beginning of period |
355.6 |
492.4 |
| Cash and cash equivalents, end of period |
212.4 |
217.4 |
|
Biomet, Inc. [Member]
|
|
|
| Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] |
|
|
| Cash flows provided by (used in) operating activities |
159.2 |
121.8 |
| Capital expenditures |
0 |
0 |
| Acquisitions, net of cash acquired - 2013 Spine Acquisition |
0 |
|
| Acquisitions, net of cash acquired |
|
0 |
| Other |
0 |
0 |
| Net cash used in investing activities |
0 |
0 |
| Proceeds under revolvers |
155.0 |
80.0 |
| Payments under revolvers |
(55.0) |
(80.0) |
| Proceeds from senior notes due 2020 and term loans |
870.5 |
3,396.2 |
| Tender/retirement of senior notes due 2017 and term loans |
(1,091.6) |
(3,423.0) |
| Payment of fees related to refinancing activities |
|
(77.8) |
| Other |
(38.1) |
(17.2) |
| Net cash used in financing activities |
(159.2) |
(121.8) |
| Effect of exchange rate changes on cash |
0 |
0 |
| Increase (decrease) in cash and cash equivalents |
0 |
0 |
| Cash and cash equivalents, beginning of period |
0 |
0 |
| Cash and cash equivalents, end of period |
0 |
0 |
|
Guarantors [Member]
|
|
|
| Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] |
|
|
| Cash flows provided by (used in) operating activities |
236.6 |
198.0 |
| Capital expenditures |
(91.7) |
(69.4) |
| Acquisitions, net of cash acquired - 2013 Spine Acquisition |
(148.8) |
|
| Acquisitions, net of cash acquired |
|
(277.5) |
| Other |
(1.4) |
(2.0) |
| Net cash used in investing activities |
(241.9) |
(348.9) |
| Proceeds under revolvers |
0 |
0 |
| Payments under revolvers |
0 |
0 |
| Proceeds from senior notes due 2020 and term loans |
0 |
0 |
| Tender/retirement of senior notes due 2017 and term loans |
0 |
0 |
| Payment of fees related to refinancing activities |
|
0 |
| Other |
0.6 |
(0.1) |
| Net cash used in financing activities |
0.6 |
(0.1) |
| Effect of exchange rate changes on cash |
0 |
0 |
| Increase (decrease) in cash and cash equivalents |
(4.7) |
(151.0) |
| Cash and cash equivalents, beginning of period |
35.3 |
190.1 |
| Cash and cash equivalents, end of period |
30.6 |
39.1 |
|
Non-Guarantors [Member]
|
|
|
| Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] |
|
|
| Cash flows provided by (used in) operating activities |
(70.2) |
(46.0) |
| Capital expenditures |
(67.1) |
(80.3) |
| Acquisitions, net of cash acquired - 2013 Spine Acquisition |
0 |
|
| Acquisitions, net of cash acquired |
|
(2.5) |
| Other |
0.1 |
(2.1) |
| Net cash used in investing activities |
(67.0) |
(84.9) |
| Proceeds under revolvers |
4.3 |
0 |
| Payments under revolvers |
(8.0) |
0 |
| Proceeds from senior notes due 2020 and term loans |
0 |
0 |
| Tender/retirement of senior notes due 2017 and term loans |
0 |
0 |
| Payment of fees related to refinancing activities |
|
0 |
| Other |
(2.3) |
(9.0) |
| Net cash used in financing activities |
(6.0) |
(9.0) |
| Effect of exchange rate changes on cash |
4.7 |
15.9 |
| Increase (decrease) in cash and cash equivalents |
(138.5) |
(124.0) |
| Cash and cash equivalents, beginning of period |
320.3 |
302.3 |
| Cash and cash equivalents, end of period |
181.8 |
178.3 |
|
Eliminations [Member]
|
|
|
| Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] |
|
|
| Cash flows provided by (used in) operating activities |
0 |
0 |
| Capital expenditures |
0 |
0 |
| Acquisitions, net of cash acquired - 2013 Spine Acquisition |
0 |
|
| Acquisitions, net of cash acquired |
|
0 |
| Other |
0 |
0 |
| Net cash used in investing activities |
0 |
0 |
| Proceeds under revolvers |
0 |
0 |
| Payments under revolvers |
0 |
0 |
| Proceeds from senior notes due 2020 and term loans |
0 |
0 |
| Tender/retirement of senior notes due 2017 and term loans |
0 |
0 |
| Payment of fees related to refinancing activities |
|
0 |
| Other |
0 |
0 |
| Net cash used in financing activities |
0 |
0 |
| Effect of exchange rate changes on cash |
0 |
0 |
| Increase (decrease) in cash and cash equivalents |
0 |
0 |
| Cash and cash equivalents, beginning of period |
0 |
0 |
| Cash and cash equivalents, end of period |
$ 0 |
$ 0 |